While others divest, Sandoz expands: "Antibiotics are the backbone of modern medicine"

Unlike many large pharmaceutical companies, Sandoz is still investing in antibiotics, most recently through the acquisition of a GSK portfolio and an expansion in European production. This business area will remain central to the company, says Carol Lynch.

Photo: Sandoz / PR

The antibiotics business at Sandoz has been on something of a rollercoaster ride over the past two years. After a spike in demand at the start of the pandemic, sales plummeted due to cancelled operations, and the company has only just started to see normalization on the market.

It might therefore seem paradoxical that Sandoz has started two of its biggest projects in years within antibiotics during this period. The first is a significant upgrade to its production facilities in Austria and Spain, and the second is the acquisition of Glaxosmithkline's cefalasporin antibiotic portfolio.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs